The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


HALF SINEMET CR

25/100 Milligram Tablet Prolonged Release

Merck Sharp & Dohme Ireland (Human Health) LimitedPA1286/009/001

Main Information

Trade NameHALF SINEMET CR
Active SubstancesLEVODOPA
CARBIDOPA
Strength25/100 Milligram
Dosage FormTablet Prolonged Release
Licence HolderMerck Sharp & Dohme Ireland (Human Health) Limited
Licence NumberPA1286/009/001

Group Information

ATC CodeN04BA02 levodopa and decarboxylase inhibitor

Status

Authorised/WithdrawnAuthorised
Licence Issued22/02/1993
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back